Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00276835 · ClinicalTrials.gov registry record · Early Phase 1
Genistein and Interleukin-2 in Treating Patients With Metastatic Melanoma or Kidney Cancer
A Early Phase 1 study of Kidney Cancer and Melanoma (Skin), sponsored by Northwestern University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT00276835 is a Early Phase 1 study of Kidney Cancer and Melanoma (Skin) that has completed, run by Northwestern University. The registered enrollment target is 15 participants, below the 880-participant average among 60 other Kidney Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00276835, a Early Phase 1 study of Kidney Cancer and Melanoma (Skin), has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Genistein may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Interleukin-2 may stimulate the white blood cells, including natural killer cells, to kill melanoma or kidney cancer cells. Giving genistein together with interleukin-2 may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving genistein together with interleukin-2 works in treating patients with metastatic melanoma or kidney cancer.
Conditions Studied
Interventions
- BIOLOGICAL High-dose interleukin-2
- DIETARY_SUPPLEMENT genistein
Study Locations (1)
Illinois
- Robert H. Lurie Comprehensive Cancer Center at Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2005-11 |
| Est. Completion | 2014-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00276835
The ClinicalTrials.gov registry entry for NCT00276835 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 880-participant average among 60 other Kidney Cancer trials with a reported enrollment target (98% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Kidney Cancer appearing as the primary indexed condition, and to 2 interventions - of which High-dose interleukin-2 is the first listed.
NCT00276835 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT00276835 about?
NCT00276835 is a clinical study titled "Genistein and Interleukin-2 in Treating Patients With Metastatic Melanoma or Kidney Cancer". RATIONALE: Genistein may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Interleukin-2 may stimulate the white blood cells, including natural killer cells, to kill melanoma or kidney cancer cells. Giving genistein togethe...
What is the current status of trial NCT00276835?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 15 participants. The study started on 2005-11. Estimated completion is 2014-01.
What conditions does trial NCT00276835 study?
This clinical trial studies the following conditions: Kidney Cancer, Melanoma (Skin).
What interventions are being tested in trial NCT00276835?
The interventions under investigation include: High-dose interleukin-2 (BIOLOGICAL), genistein (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00276835?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00276835 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Patient Navigation Program to Improve Clinical Trial Enrollment in Cancer Patients
RECRUITING · NA
-
Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform
RECRUITING
-
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
RECRUITING
-
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders
RECRUITING
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
-
Genetic Analysis of Birt Hogg-Dube Syndrome and Characterization of Predisposition to Kidney Cancer
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.